Wrightson raid hints at biotech 'super-company'

Wrightson announced its $1.31-a-share stand in the market on Wednesday and finished the day with 15.05%.

It said its Genesis investment was aimed at "providing an impetus" for more collaboration in agricultural biotechnology.

The move is likely to have been approved by its 19.9% shareholder, Fonterra. Both Wrightson and Fonterra subsidiary RD1 have biotech research arms and market observers have speculated Fonterra will eventually take over Wrightson and separate the rural services and biotech divisions.

Genesis' shares have languished below the $1.70 value of its cash reserves of about $36.3 million. They traded at 97c immediately before the Wrightson stand was announced.

British trials of Genesis' Avac eczema treatment showed the drug to be safe and well-tolerated.

Comments from our readers

No comments yet

Add your comment:

Your name:
Your email:	Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Anti-spam verification:

Type the text you see in the image into the field below. You are asked to do this in order to verify that this enquiry is not being performed by an automated process.

Related News:

PEB - Chair to Seek Re-Election; Director Nominations
Devon Funds Morning Note - 16 June 2025
TRU - Key Markets Update
THL receives unsolicited non-binding offer
June 16th Morning Report
CHATHAM ANNOUNCES NON-BROKERED PRIVATE PLACEMENT
Radius Care Upgrades FY26 Outlook
June 13th Morning Report
June 12th Morning Report
PGW Governance Update